Association of proton pump inhibitors with renal dysfunction: a cross-sectional study
Keywords:Proton pump inhibitors, Renal dysfunction, Serum creatinine, Estimated glomerular filtration rate
Background: Proton pump inhibitors are the most frequently prescribed class of medications for prescription and over-the-counter, and the data suggest that comorbidities, polypharmacy, self-medication, no clear indications and duration beyond the recommended guidelines PPIs use are associated with renal dysfunction. Aim was to study the proportion of renal dysfunction among patients using oral PPIs and determine the association between the duration of oral PPIs use and the severity of renal dysfunction.
Methods: The data collection of 250 patients was done at the time of contact, which included demographic profiles, complete medical history, physical examination, and laboratory investigation in this study. For analysis, name of oral PPIs used, duration and dosage of oral PPIs therapy, laboratory values of serum blood urea, serum creatinine, eGFR, and serum electrolytes parameters have been considered.
Results: Amongst 250 patients with PPIs used for a week, 23 patients showed mildly reduced kidney function (p=0.000), PPIs used for >1 to 2 weeks, 29 patients showed grade 2 kidney function (p=0.001), while PPIs used for >2-3 weeks only two patients showed grade 3 kidney function (p=0.44). Patients aged >50 years in all groups showed grade 2 renal function, regardless of the duration of PPIs use. Increasing age, males, rural, smoking, and alcoholics were the risk factors for renal dysfunction. PPIs use significantly impacts eGFR.
Conclusions: Collectively, this study found a significant association between PPIs use and renal dysfunction. PPIs used for >2 weeks in elderly patients have shown a 4−fold increased risk of developing renal dysfunction.
Valle JD. Peptic Ulcer Disease and Related Disorders. New York: McGraw-Hill Education; 2018.
Wallace JL, Sharkey KA. Pharmacotherapy of gastric acidity, peptic ulcers and gastroesophageal reflux disease, Goodman & Gilman’s. The pharmacological basis of therapeutics. 12th ed. San Diego: McGraw-Hill Companies; 2011:1309-22.
Forgacs I, Loganayagam A. Overprescribing proton pump inhibitors. Lancet. 2008;320(8):45-9.
Der G. An overview of proton pump inhibitors. Gastroenterol Nurs. 2003;26(5):182-90.
Ford AC. Evaluation and management of dyspepsia. Therap Adv Gastroenterol. 2010;3(2):87-98.
Ito T, Jensen RT. Association of long-term proton pump inhibitor therapy with bone fractures and effects on absorption of calcium, vitamin B12, iron, and magnesium. Curr Gastroenterol Rep. 2010;12(6):448-57.
Moayyedi P, Eikelboom JW, Bosch J, Connolly SJ, Dyal L, Shestakovska O, et al. Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin. Gastroenterology. 2019;157(3):682-91.
Drug utilisation subcommittee (dusc) database. Available at: www.australianprescriber.com /magazine/34/6/artid/1063. Accessed on 20 February 2023.
Singh R, Kothari M. Use of proton pump inhibitors with dexamethasone in patients with COVID-19 pneumonia: contributions to long-term polypharmacy. Cureus. 2022;14(5): e24661.
Grant K, Al-Adhami N, Tordoff J, Livesey J, Barbezat G, Reith D. Continuation of proton pump inhibitors from hospital to community. Pharm World Sci. 2006;28(4):189-93.
Malik TF, Gnanapandithan K, Singh K. Peptic Ulcer Disease. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2023.
Nochaiwong S, Ruengorn C, Awiphan R, Koyratkoson K, Chaisai C, Noppakun K, et al. The association between proton pump inhibitor use and the risk of adverse kidney outcomes: a systematic review and meta-analysis. Nephrol Dial Transplant. 2018;33(2): 331-42.
Batuwitage BT, Kingham JG, Morgan NE, Bartlett RL. Inappropriate prescribing of proton pump inhibitors in primary care. Postgrad Med J. 2007;83(975):66-8.
Ahrens D, Chenot JF, Behrens G, Grimmsmann T, Kochen MM. Appropriateness of treatment recommendations for PPI in hospital discharge letters. Eur J Clin Pharmacol. 2010;66(12):1265-71.
Pasina L, Nobili A, Tettamanti M, Salerno F, Corrao S, Marengoni A, et al. Prevalence and appropriateness of drug prescriptions for peptic ulcer and gastro-esophageal reflux disease in a cohort of hospitalized elderly. Eur J Intern Med. 2011;22(2):205-10.
George CJ, Korc B, Ross JS. Appropriate proton pump inhibitor use among older adults: a retrospective chart review. Am J Geriatr Pharmacother. 2008;6(5):249-54.
Hollingworth S, Duncan EL, Martin JH. Marked increase in proton pump inhibitors use in Australia. Pharmacoepidemiol Drug Saf. 2010;19(10):1019-24.
Grootendorst DC, Michels WM, Richardson JD, Jager KJ, Boeschoten EW, Dekker FW, Krediet RT; NECOSAD Study Group. The MDRD formula does not reflect GFR in ESRD patients. Nephrol Dial Transplant. 2011;26(6):1932-7.
Lazarus B, Chen Y, Wilson FP, Sang Y, Chang AR, Coresh J, Grams ME. Proton Pump Inhibitor Use and the Risk of Chronic Kidney Disease. JAMA Intern Med. 2016;176(2):238-46.
Sowjanya G, Amulya K, Priyanka R. A prospective observational study on the association of the renal disease with the use of proton pump inhibitors in a tertiary care hospital. Indian J Pharm Pract. 2019; 12(2):34-9.
Xie Y, Bowe B, Li T, Xian H, Yan Y, Al-Aly Z. Long-term kidney outcomes among users of proton pump inhibitors without intervening acute kidney injury. Kidney Int. 2017;91(6):1482-94.
Avinash A, Patil N, Kunder SK, Balaji O, Tilak A, Sori RK, et al. A Retrospective Study to Assess the Effect of Proton Pump Inhibitors on Renal Profile in a South Indian Hospital. J Clin Diagn Res. 2017;11(4):FC09-FC12.
Xie Y, Bowe B, Li T, Xian H, Balasubramanian S, Al-Aly Z. Proton Pump Inhibitors and Risk of Incident CKD and Progression to ESRD. J Am Soc Nephrol. 2016;27(10):3153-63.
Wakabayashi T, Hosohata K, Oyama S, Inada A, Niinomi I, Kambara H, et al. Association between a low dose of proton pump inhibitors and kidney function decline in elderly hypertensive patients: a retrospective observational study. J Int Med Res. 2021;49(4):300.
Klepser DG, Collier DS, Cochran GL. Proton pump inhibitors and acute kidney injury: a nested case-control study. BMC Nephrol. 2013;14:150.
Antoniou T, Macdonald EM, Hollands S, Gomes T, Mamdani MM, Garg AX, et al. Proton pump inhibitors and the risk of acute kidney injury in older patients: a population-based cohort study. CMAJ. 2015;3(2): E166-71.
Peng YC, Lin CL, Yeh HZ, Chang CS, Wu YL, Kao CH. Association Between the Use of Proton Pump Inhibitors and the Risk of ESRD in Renal Diseases: A Population-Based, Case-Control Study. Medicine (Baltimore). 2016;95(15):e3363.
Arora P, Gupta A, Golzy M, Patel N, Carter RL, Jalal K, Lohr JW. Proton pump inhibitors are associated with increased risk of development of chronic kidney disease. BMC Nephrol. 2016;17(1):112.
Wu B, Li D, Xu T, Luo M, He Z, Li Y. Proton pump inhibitors associated acute kidney injury and chronic kidney disease: data mining of US FDA adverse event reporting system. Sci Rep. 2021;11(1):3690.
Lee J, Mark RG, Celi LA, Danziger J. Proton Pump Inhibitors Are Not Associated With Acute Kidney Injury in Critical Illness. J Clin Pharmacol. 2016; 56(12):1500-6.
Antoniou T, Macdonald EM, Hollands S, Gomes T, Mamdani MM, Garg AX, et al. Proton pump inhibitors and the risk of acute kidney injury in older patients: a population-based cohort study. CMAJ Open. 2015; 3(2):E166-71.